He et al., 2017 - Google Patents
Lactobacillus rhamnosus GG supernatant enhance neonatal resistance to systemic Escherichia coli K1 infection by accelerating development of intestinal defenseHe et al., 2017
View HTML- Document ID
- 7653840381374987801
- Author
- He X
- Zeng Q
- Puthiyakunnon S
- Zeng Z
- Yang W
- Qiu J
- Du L
- Boddu S
- Wu T
- Cai D
- Huang S
- Cao H
- Publication year
- Publication venue
- Scientific reports
External Links
Snippet
The objective of this study was to determine whether Lactobacillus rhamnosus GG culture supernatant (LCS) has a preventive effect against gut-derived systemic neonatal Escherichia coli (E. coli) K1 infection. The preventive effects were evaluated in human …
- 241000617590 Escherichia coli K1 0 title abstract description 129
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Lactobacillus rhamnosus GG supernatant enhance neonatal resistance to systemic Escherichia coli K1 infection by accelerating development of intestinal defense | |
| Pluta et al. | Gut microbiota and pro/prebiotics in Alzheimer’s disease | |
| Anand et al. | Diet, microbiota and gut-lung connection | |
| Garcia-Gutierrez et al. | Autism spectrum disorder associated with gut microbiota at immune, metabolomic, and neuroactive level | |
| Sun et al. | Dysbiosis of gut microbiota and microbial metabolites in Parkinson’s Disease | |
| Tan et al. | Novel strains of Bacteroides fragilis and Bacteroides ovatus alleviate the LPS-induced inflammation in mice | |
| Guo et al. | Secretions of Bifidobacterium infantis and Lactobacillus acidophilus protect intestinal epithelial barrier function | |
| Dixit et al. | Restoration of dysbiotic human gut microbiome for homeostasis | |
| Manko et al. | Giardia co-infection promotes the secretion of antimicrobial peptides beta-defensin 2 and trefoil factor 3 and attenuates attaching and effacing bacteria-induced intestinal disease | |
| Fan et al. | Bacteroides fragilis strain ZY-312 defense against Cronobacter sakazakii-induced necrotizing enterocolitis in vitro and in a neonatal rat model | |
| Scaldaferri et al. | Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility | |
| Xu et al. | The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential | |
| Wlodarska et al. | Host immune response to antibiotic perturbation of the microbiota | |
| Bellocchi et al. | Update on the gastrointestinal microbiome in systemic sclerosis | |
| Pereira et al. | Effect of dietary additives on intestinal permeability in both Drosophila and a human cell co-culture | |
| Reid et al. | The rationale for probiotics improving reproductive health and pregnancy outcome | |
| Gunasekaran et al. | Hyaluronan 35 kDa enhances epithelial barrier function and protects against the development of murine necrotizing enterocolitis | |
| Cinque et al. | Production conditions affect the in vitro anti-tumoral effects of a high concentration multi-strain probiotic preparation | |
| Lorentz et al. | Myosin light chain kinase knockout improves gut barrier function and confers a survival advantage in polymicrobial sepsis | |
| Salzman | The role of the microbiome in immune cell development | |
| Ghotaslou et al. | The metabolic, protective, and immune functions of Akkermansia muciniphila | |
| Omata et al. | Parenteral nutrition suppresses the bactericidal response of the small intestine | |
| Zhang et al. | Foodborne carbon dot exposure induces insulin resistance through gut microbiota dysbiosis and damaged intestinal mucus layer | |
| Rammohan et al. | Synbiotics in surgery for chronic pancreatitis: are they truly effective? A single-blind prospective randomized control trial | |
| Pang et al. | Immunomodulatory effects of Escherichia coli ATCC 25922 on allergic airway inflammation in a mouse model |